Over the years, it was widely demonstrated that the activation of the SLC22A17 gene partners (NGAL and MMP-9) may promote different malignancies, including glioma, endometrial cancer, lung adenocarcinoma, and gastric cancer [53–56]. This evidence concerns the gene LCN2 and glioma.